Morgan Stanley
NWBO

Morgan Stanley’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Morgan Stanley’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-213,755
Closed -$116K – 6733
2016
Q3 		$116K Sell
213,755
-16,423
-7% -$7.51K ﹤0.01% 5251
2016
Q2 		$134K Sell
230,178
-86,720
-27% -$92.6K ﹤0.01% 5112
2016
Q1 		$462K Sell
316,898
-38,865
-11% -$76.7K ﹤0.01% 4500
2015
Q4 		$1.14M Buy
355,763
+125,694
+55% +$604K ﹤0.01% 3960
2015
Q3 		$1.44M Sell
230,069
-66,254
-22% -$619K ﹤0.01% 3805
2015
Q2 		$2.94M Buy
296,323
+94,502
+47% +$828K ﹤0.01% 3262
2015
Q1 		$1.49M Sell
201,821
-76,658
-28% -$516K ﹤0.01% 3830
2014
Q4 		$1.49M Buy
278,479
+43,093
+18% +$221K ﹤0.01% 3805
2014
Q3 		$1.18M Buy
235,386
+17,172
+8% +$106K ﹤0.01% 3899
2014
Q2 		$1.46M Buy
218,214
+5,554
+3% +$35.4K ﹤0.01% 3735
2014
Q1 		$1.54M Buy
212,660
+179,711
+545% +$1.07M ﹤0.01% 3647
2013
Q4 		$124K Buy
+32,949
New +$128K ﹤0.01% 5264

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BW
Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

Morgan Stanley's NWBO Position: Q4 2016 in Review

Morgan Stanley sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 213,755 shares — an estimated $116K sold.

Morgan Stanley first reported a position in NWBO in Q4 2013 and held it in 12 quarters. The position peaked at $2.94M in Q2 2015. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • Morgan Stanley reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • Morgan Stanley sold 213,755 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $116K.
  • Morgan Stanley first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2013 and held it in 12 quarters.
  • Morgan Stanley's Northwest Biotherapeutics, Inc. Common stock position peaked at $2.94M in Q2 2015.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Morgan Stanley's 13F filing for Q4 2016, filed 13 Feb 2017.